Biomaterials company Sealonix has closed on $20 million in series A funding for the development of its next generation of hemostatic sealants for surgical use.
The initial product is a sealant patch providing rapid hemostasis for abdominopelvic and orthopedic procedures, according to a May 12 news release from Sealonix. The proceeds from the round will be used to grow the development team and execute clinical trials.
The funding round was led by Excelestar Ventures.